Page 17 - Cipla

Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand

Cipla Gulf will be responsible for commercialisation of patented biosimilars of the biologic medicine brands -- Aflibercept, Ustekimumab,Denosumab and Golimumab.

Cipla receives USFDA nod for nasal spray for treating migraine attacks

Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment of migraine attacks

Cipla plans to double share from consumer health business in 5 years

Transitioning brands from prescription and trade generics to over-the-counter

Domestic drug market growth slows top 4.5% in January, some therapies drag

Respiratory segment and anti-infectives contract; Cardiac, anti-diabetic growth rates plummet

Nifty Pharma index surges 4%; Sun Pharma, Cipla hit 52-week highs

At 12:57 pm, Nifty Pharma index, the top gainer among sectoral indices, was up 4.2 per cent, as compared to 1.3 per cent gain in the benchmark Nifty50 index

Cipla's net profit zooms 113% in December quarter; revenue up 18%

The total revenue from operations came in at Rs 5,169 crore and the net profit stood at Rs 748 crore, up 113 per cent.

Stocks to watch: TCS, Wipro, Avenue Supermarts, Tata Steel, Vedanta, Cipla

Bharti Airtel announced the appointment of Pradipt Kapoor as its Chief Information Officer

Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost

Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities

Cipla recalls over 5.8 lakh packets of gastric ulcer treatment drug in US

Drug major Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market, as per a report by the US Food and Drug Administration.

Trading calls by Ajit Mishra of Religare Broking: Buy Cipla, Eicher Motors

Eicher Motors' stock has been witnessing profit taking for the last one month, and is likely to see a gradual recovery from hereon

Nifty outlook & trading ideas by Vinay Rajani of HDFC Securities

Upside target for Nifty is seen at 14,300 odd levels, which happens to be the 138.2 per cent Fibonacci retracement of the downswing seen from 12,430 to 7,511

Cipla rallies 5% after settling litigation with Bristol Myers in US

Bristol Myers (Celgene) will provide Cipla with a license to sell generic volume-limited amounts of gRevlimid capsules in the US sometime after March 2022, subject to regulatory approval

Cipla settles blood cancer drug litigation with Bristol Myers in US

As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved

Chronic portfolio may help Cipla sustain growth outperformance in near term

Margin gains in the September quarter too are expected to continue

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Top headlines: Passenger vehicles sales dip; Finance Commission report out

The Bombay High Court refused to grant interim bail to TV journalist Arnab Goswami.

Demand for Covid-19 drug Remdesivir rising sharply in India, says Cipla

Cipla's version, Cipremi, was commercially launched in July and costs just above $50 per 100 mg vial

Top headlines: Free health checkup in cos soon; data breach at BigBasket

From new labour laws promising free annual health checkups to markets poised for fresh all-time highs as investors cheer Biden win, here are top headlines this morning

Cipla expects surge in demand for respiratory drugs, inhalers in winter

The firm enjoys a massive 68.7 per cent market share in the respiratory inhalation segment in India and has started working on aligning supplies so that there is no shortage of these critical medicine

Drugmaker Cipla eyes digital adoption to sustain growth through Covid-19

The drug firm has earmarked digital adoption and resilient operations as first of the key priorities for the coming quarters